Clinical trials
Locally Recurrent Rectal Cancer clinical trials
Below are recruiting locally recurrent rectal cancer clinical trials, each written for real people, not researchers. We’re tracking 62 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05585814RecruitingPhase 2
New chemo plus immunotherapy before rectal surgery
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
ShanghaiAges 18–75 - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06767007RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
Guangzhou, GuangdongAges 18–75 - NCT07454720RecruitingPhase 2/Phase 3
Study of Adebrelimab with SHR-8068 and chemoradiation before surgery for rectal cancer
This trial tests whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to standard chemoradiation before surgery can improve outcomes for adults with locally advanced rectal cancer that can be surgically removed.
Wuhan, HubeiAges 18–75 - NCT07183865RecruitingPhase 2
Radiation, chemo, and immunotherapy for recurrent rectal cancer
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04695782RecruitingPhase 2
Proton radiation for recurrent rectal cancer in the pelvis
This trial studies “pencil beam” proton radiation for rectal cancer that has come back in the pelvis after you already had radiation. It aims to control the recurrence while trying to limit harm to nearby organs.
AarhusAges 18 years+ - NCT06459869RecruitingPhase 1
NG-350A plus chemoradiotherapy for advanced rectal cancer
This trial is testing a new virus-based therapy (NG-350A) combined with standard chemoradiotherapy for people with locally advanced rectal cancer. It aims to see if the combination is safe and can help shrink tumors before surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06840665RecruitingPhase 2
Radiation plus immunotherapy and chemo for rectal cancer
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07297004RecruitingPhase 2
Targeted radiation for recurrent rectal cancer
This trial tests targeted radiation (SBRT) for people whose rectal cancer has come back in the pelvis and cannot be surgically removed. The goal is to see if this focused radiation can control the tumor with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07721181Recruiting
STEP-UP: Higher radiation for recurrent rectal cancer
This trial tests giving a higher dose of radiation to people whose rectal cancer has come back in the pelvis after surgery and cannot be removed. It aims to see if more radiation can help control the tumor when surgery is not an option.
ArnhemAges 18 years+ - NCT03516708RecruitingPhase 1/Phase 2
Epacadostat with pre-op radiation for locally advanced rectal cancer
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Orange, CaliforniaAges 18 years+ - NCT04288999RecruitingPhase 3
Surgery plus chemo versus chemo-radiation then surgery for recurrent rectal cancer
This study compares two treatment plans for locally recurrent rectal cancer: (1) surgery plus chemo, or (2) chemo plus radiation first, then surgery, followed by chemo. It aims to see which approach works better in controlling the cancer and helping patients recover.
ChibaAges 20–80 - NCT04389086RecruitingPhase 3
Chemotherapy before surgery for recurring rectal cancer
This trial tests an “induction chemotherapy” treatment before surgery for people whose rectal cancer has come back in the local area. The goal is to shrink/control the cancer early and improve outcomes after treatment.
GhentAges 18 years+ - NCT05136326RecruitingPhase 2
Pre-surgery chemo-radiation for rectal cancer without MGMT
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
MilanAges 18 years+ - NCT05148767RecruitingPhase 4
UGT1A1-guided irinotecan for locally advanced rectal cancer
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Hangzhou, ZhejiangAges 18–75 - NCT05576480RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for rectal cancer without mismatch repair
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
Shanghai, None SelectedAges 18–75 - NCT05628038RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05731726RecruitingPhase 2
New treatment before surgery for locally advanced rectal cancer
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
Hangzhou, ZhejiangAges 18–75 - NCT05984485RecruitingPhase 3
Surgery vs chemo before surgery for low-risk rectal cancer
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06052332Recruiting
Comparing two pre-surgery treatments for older adults with rectal cancer
This study compares two approaches to treating rectal cancer in people age 70 and older who have not yet had surgery. One approach gives chemotherapy and radiation before surgery, and the other adds more chemotherapy after radiation. The goal is to find which plan works better with fewer side effects.
Antwerp, AntwerpenAges 70 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+
Hear when a new Locally Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally recurrent rectal cancer?
- Yes. Clin2 currently lists 62 recruiting locally recurrent rectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally recurrent rectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally recurrent rectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.